We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients.
- Authors
Jahaj, Edison; Vassiliou, Alice G.; Keskinidou, Chrysi; Gallos, Parisis; Vrettou, Charikleia S.; Tsipilis, Stamatios; Mastora, Zafeiria; Orfanos, Stylianos E.; Dimopoulou, Ioanna; Kotanidou, Anastasia
- Abstract
Studies have hypothesized a potential role of the interleukin (IL)-23/17 axis in coronavirus disease 2019 (COVID-19). However, to date, levels of IL-23 and 17 have not been compared between critically ill COVID-19 patients and critically ill non-COVID-19 patients. IL-23 and 17 were measured on admission to the intensive care unit (ICU) in critically ill COVID-19 (N = 38) and critically ill non-COVID-19 (N = 34) patients with an equal critical illness severity. Critically ill non-COVID-19 patients did not have sepsis or septic shock on ICU admission. None of the enrolled patients had previously received corticosteroids. In our study, circulating IL-17 levels were higher in the COVID-19 patients. More specifically, critically ill COVID-19 patients had levels of 0.78 (0.05–1.8) pg/mL compared to 0.11 (0.05–0.9) pg/mL in the critically ill non-COVID-19 patients (p = 0.04). In contrast, IL-23 levels were comparable between groups. A group of patients hospitalized in the specialized COVID-19 clinic (N = 16) was also used to evaluate IL-17 and IL-23 levels with respect to COVID-19 severity. Non-critically ill COVID-19 patients had undetectable levels of both cytokines. Our results support the notion of inhibiting IL-17 in critical COVID-19 infection.
- Subjects
COVID-19; CRITICALLY ill; INTERLEUKIN-17; SEPTIC shock; INTENSIVE care units
- Publication
Journal of Personalized Medicine, 2021, Vol 11, Issue 9, p891
- ISSN
2075-4426
- Publication type
Article
- DOI
10.3390/jpm11090891